|
Gene: ATP2C1 |
Gene summary for ATP2C1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ATP2C1 | Gene ID | 27032 |
Gene name | ATPase secretory pathway Ca2+ transporting 1 | |
Gene Alias | ATP2C1A | |
Cytomap | 3q22.1 | |
Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | P98194 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
27032 | ATP2C1 | CA_HPV_2 | Human | Cervix | CC | 4.48e-02 | 2.63e-01 | 0.0391 |
27032 | ATP2C1 | CCI_1 | Human | Cervix | CC | 9.64e-04 | 7.07e-01 | 0.528 |
27032 | ATP2C1 | CCI_2 | Human | Cervix | CC | 6.77e-10 | 1.12e+00 | 0.5249 |
27032 | ATP2C1 | CCI_3 | Human | Cervix | CC | 1.13e-15 | 1.17e+00 | 0.516 |
27032 | ATP2C1 | Tumor | Human | Cervix | CC | 6.97e-09 | 4.55e-01 | 0.1241 |
27032 | ATP2C1 | sample3 | Human | Cervix | CC | 7.38e-16 | 4.77e-01 | 0.1387 |
27032 | ATP2C1 | T3 | Human | Cervix | CC | 4.87e-12 | 4.55e-01 | 0.1389 |
27032 | ATP2C1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.78e-06 | -4.23e-01 | 0.0155 |
27032 | ATP2C1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.82e-03 | -4.50e-01 | -0.1207 |
27032 | ATP2C1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.30e-02 | -3.87e-01 | -0.1464 |
27032 | ATP2C1 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.42e-02 | -3.33e-01 | -0.1001 |
27032 | ATP2C1 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.02e-04 | -3.91e-01 | 0.096 |
27032 | ATP2C1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.33e-03 | -3.74e-01 | 0.0338 |
27032 | ATP2C1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 8.09e-03 | -3.22e-01 | 0.0674 |
27032 | ATP2C1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.12e-12 | -5.16e-01 | 0.3005 |
27032 | ATP2C1 | A015-C-203 | Human | Colorectum | FAP | 2.36e-17 | -3.35e-01 | -0.1294 |
27032 | ATP2C1 | A015-C-204 | Human | Colorectum | FAP | 3.63e-04 | -2.99e-01 | -0.0228 |
27032 | ATP2C1 | A014-C-040 | Human | Colorectum | FAP | 4.08e-02 | -3.64e-01 | -0.1184 |
27032 | ATP2C1 | A002-C-201 | Human | Colorectum | FAP | 3.31e-08 | -2.85e-01 | 0.0324 |
27032 | ATP2C1 | A001-C-119 | Human | Colorectum | FAP | 5.92e-06 | -3.72e-01 | -0.1557 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
GO:19043779 | Cervix | CC | positive regulation of protein localization to cell periphery | 24/2311 | 69/18723 | 1.21e-06 | 4.15e-05 | 24 |
GO:00315328 | Cervix | CC | actin cytoskeleton reorganization | 31/2311 | 107/18723 | 3.34e-06 | 8.99e-05 | 31 |
GO:19030788 | Cervix | CC | positive regulation of protein localization to plasma membrane | 21/2311 | 62/18723 | 8.91e-06 | 2.03e-04 | 21 |
GO:19054778 | Cervix | CC | positive regulation of protein localization to membrane | 29/2311 | 106/18723 | 2.29e-05 | 4.01e-04 | 29 |
GO:00988767 | Cervix | CC | vesicle-mediated transport to the plasma membrane | 34/2311 | 136/18723 | 3.75e-05 | 5.91e-04 | 34 |
GO:00068927 | Cervix | CC | post-Golgi vesicle-mediated transport | 28/2311 | 104/18723 | 4.31e-05 | 6.61e-04 | 28 |
GO:00431228 | Cervix | CC | regulation of I-kappaB kinase/NF-kappaB signaling | 53/2311 | 249/18723 | 4.50e-05 | 6.87e-04 | 53 |
GO:00901509 | Cervix | CC | establishment of protein localization to membrane | 54/2311 | 260/18723 | 7.67e-05 | 1.05e-03 | 54 |
GO:19030768 | Cervix | CC | regulation of protein localization to plasma membrane | 27/2311 | 104/18723 | 1.15e-04 | 1.44e-03 | 27 |
GO:00072497 | Cervix | CC | I-kappaB kinase/NF-kappaB signaling | 56/2311 | 281/18723 | 1.81e-04 | 2.12e-03 | 56 |
GO:00481938 | Cervix | CC | Golgi vesicle transport | 58/2311 | 296/18723 | 2.24e-04 | 2.54e-03 | 58 |
GO:19043758 | Cervix | CC | regulation of protein localization to cell periphery | 30/2311 | 125/18723 | 2.28e-04 | 2.56e-03 | 30 |
GO:19054758 | Cervix | CC | regulation of protein localization to membrane | 36/2311 | 175/18723 | 1.33e-03 | 1.05e-02 | 36 |
GO:00068936 | Cervix | CC | Golgi to plasma membrane transport | 16/2311 | 60/18723 | 2.00e-03 | 1.46e-02 | 16 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP2C1 | insertion | Frame_Shift_Ins | novel | c.2556dupT | p.Asp853Ter | p.D853* | P98194 | protein_coding | TCGA-AX-A2IN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
ATP2C1 | insertion | Frame_Shift_Ins | novel | c.177dupA | p.Ala60SerfsTer3 | p.A60Sfs*3 | P98194 | protein_coding | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ATP2C1 | SNV | Missense_Mutation | novel | c.2719C>G | p.Leu907Val | p.L907V | P98194 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-DD-A73B-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ATP2C1 | SNV | Missense_Mutation | novel | c.1279N>T | p.Val427Phe | p.V427F | P98194 | protein_coding | tolerated(0.06) | benign(0.361) | TCGA-DD-AACV-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
ATP2C1 | SNV | Missense_Mutation | novel | c.1642A>C | p.Lys548Gln | p.K548Q | P98194 | protein_coding | deleterious(0.04) | benign(0.098) | TCGA-05-4397-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ATP2C1 | SNV | Missense_Mutation | c.965N>T | p.Gly322Val | p.G322V | P98194 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-05-4410-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ATP2C1 | SNV | Missense_Mutation | novel | c.1764N>C | p.Glu588Asp | p.E588D | P98194 | protein_coding | tolerated(0.25) | benign(0.17) | TCGA-53-A4EZ-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
ATP2C1 | SNV | Missense_Mutation | c.1700N>A | p.Leu567Gln | p.L567Q | P98194 | protein_coding | tolerated(0.1) | possibly_damaging(0.861) | TCGA-69-7978-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ATP2C1 | SNV | Missense_Mutation | novel | c.1015G>A | p.Ala339Thr | p.A339T | P98194 | protein_coding | deleterious(0) | possibly_damaging(0.767) | TCGA-73-4662-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ATP2C1 | SNV | Missense_Mutation | c.1173N>C | p.Lys391Asn | p.K391N | P98194 | protein_coding | tolerated(0.15) | benign(0.251) | TCGA-78-7156-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | ENFLURANE | ENFLURANE | ||
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | ISOFLURANE | ISOFLURANE | ||
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | SEVOFLURANE | SEVOFLURANE | ||
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | ISOFLURANE | ISOFLURANE | ||
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | ENFLURANE | ENFLURANE | ||
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | SEVOFLURANE | SEVOFLURANE | ||
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | DESFLURANE | DESFLURANE | ||
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | DESFLURANE | DESFLURANE |
Page: 1 |